Increased leukocyte ABCA1 gene expression in post-menopausal women on hormone replacement therapy

References

• Marcil M, Brooks-Wilson A, Clee SM, Roomp K, Zhang LH, Yu L, Collins JA, van Dam M, Molhuizen HO, Loubste O. Mutations in the ABC 1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999;354:1341–1346.
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 2003;52:223–261.
   Google Scholar
• Bortnick AE, Rothblat GH, Stoudt G, Hoppe KL, Royer LJ, McNeish J, Francone OL. The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines. J Biol Chem 2000;275:28634–28640.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453–461.
   PubMed Web of Science ®Google Scholar
• Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–1037.
   PubMed Web of Science ®Google Scholar
• Sullivan JM, Zwaag RV, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM. Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med 1990;150:2557–2562.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 2003;19:55–72.
   Google Scholar
• The Writing Group for the PEPI Trial, Miller VT, LaRosa J, Barnabei V, Kessler C, Levin G, Smith-Roth A, Griffin M, Stoy DB, Bush T. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1995;273:199–208.
   PubMed Web of Science ®Google Scholar
• Espeland MA, Marcovina SM, Miller V, Wood PD, Wasilauskas C, Sherwin R, Schrott H, Bush TL. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation 1998;97:979–986.
   PubMed Web of Science ®Google Scholar
• Lamon-Fava S, Postfai B, Diffenderfer M, DeLuca C, O'Connor J Jr, Welty FK, Dolnikowski GG, Barrett PH, Schaefer EJ. Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal women. Arterioscler Thromb Vasc Biol 2006;26:385–391.
   PubMed Web of Science ®Google Scholar
• Srivastava RA. Estrogen-induced regulation of the ATP-binding cassette transporter A1 (ABCA1) in mice: a possible mechanism of atheroprotection by estrogen. Mol Cell Biochem 2002;240:67–73.
   PubMed Web of Science ®Google Scholar
• Su YR, Dove DE, Major AS, Hasty AH, Boone B, Linton MF, Fazio S. Reduced ABCA1-mediated cholesterol efflux and accelerated atherosclerosis in apolipoprotein E-deficient mice lacking macrophage-derived ACAT1. Circulation 2005;111:2373–2381.
   PubMed Web of Science ®Google Scholar
• Albrecht C, Soumian S, Amey JS, Sardini A, Higgins CF, Davies AH, Gibbs RG. ABCA1 expression in carotid atherosclerotic plaques. Stroke 2004;35:2801–2806.
   PubMed Web of Science ®Google Scholar
• Mohammad K, Sadat Hashemi SM, Farahani FK. Age at natural menopause in Iran. Maturitas 2004;49:321–326.
   PubMed Web of Science ®Google Scholar
• Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Aragaki SA, Brzyski RG, Brzyski AZ. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839–1854.
   PubMed Web of Science ®Google Scholar
• Rifai N, Warnick G. Lipids, lipoproteins, apolipoproteins, and other cardiovascular risk factors. Tietz textbook of clinical chemistryIn: Burtis C, Ashwood E, Bruns D, editors. Philadelphia: Elsevier Saunders; 2006. pp 903–968.
   Google Scholar
• Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195–1198.
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47–63.
   PubMed Web of Science ®Google Scholar
• Gibbs RB. Estrogen therapy and cognition: a review of the cholinergic hypothesis. Endocrinol Rev 2010;31:224–253.
   PubMed Web of Science ®Google Scholar
• Gass MLS, Bassuk SS, Manson JE. Reassessing benefits and risks of hormone therapy. Am J Lifestyle Med 2009;3:29–43.
   Google Scholar
• Rijpkema AHM, van der Sanden AA, Ruijs AHC. Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990;12:259–285.
   PubMed Web of Science ®Google Scholar
• Sumino H, Ichikawa S, Itoh H, Utsugi T, Ohyama Y, Umeda M, Nakamura T, Kanda T, Mizunuma H, Tomono S. Hormone replacement therapy decreases insulin resistance and lipid metabolism in Japanese postmenopausal women with impaired and normal glucose tolerance. Horm Res 2003;60:134–142.
   PubMed Web of Science ®Google Scholar
• Loh FH, Chen LH, Yu SL, Jorgensen LN. The efficacy of two dosages of a continuous combined hormone replacement regimen. Maturitas 2002;41:123–131.
   PubMed Web of Science ®Google Scholar
• Wolfe BM, Barrett PH, Laurier L, Huff MW. Effects of continuous conjugated estrogen and micronized progesterone therapy upon lipoprotein metabolism in postmenopausal women. J Lipid Res 2000;41:368–375.
   PubMed Web of Science ®Google Scholar
• Park JS, Jung HH, Yang WS, Kim SB, Min WK, Chi HS. Effects of hormonal replacement therapy on lipid and haemostatic factors in post-menopausal ESRD patients. Nephrol Dial Transplant 2000;15:1835–1840.
   PubMed Web of Science ®Google Scholar
• Ulloa N, Arteaga E, Bustos P, Duran-Sandoval D, Schulze K, Castro G, Jauhiainen M, Fruchart JC, Calvo C. Sequential estrogen-progestin replacement therapy in healthy postmenopausal women: effects on cholesterol efflux capacity and key proteins regulating high-density lipoprotein levels. Metabolism 2002;51:1410–1417.
   PubMed Web of Science ®Google Scholar
• Schaefer EJ, Foster DM, Zech LA. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 1983;57:262–267.
   PubMed Web of Science ®Google Scholar
• Ulloa N, Verdugo C, Rios M, Sepulveda J, Sepulveda S, Naveas R, Calvo C. Increased activity of lecithin:cholesterol acyltransferase during short-term oral estrogen progestin replacement therapy in a group of postmenopausal women. Metabolism 1998;47:297–300.
   PubMed Web of Science ®Google Scholar
• Jones DR, Schmidt RJ, Pickard RT, Foxworthy PS, Eacho PI. Estrogen receptor-mediated repression of human hepatic lipase gene transcription. J Lipid Res 2002;43:383–391.
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–534.
   PubMed Web of Science ®Google Scholar
• Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583–1587.
   PubMed Web of Science ®Google Scholar